Infiltrating regulatory T cell numbers is not a factor to predict patient's survival in oesophageal squamous cell carcinoma by Yoshioka, T et al.
Infiltrating regulatory T cell numbers is not a factor to predict
patient’s survival in oesophageal squamous cell carcinoma
T Yoshioka*,1, M Miyamoto
1, Y Cho
1, K Ishikawa
1, T Tsuchikawa
1, M Kadoya
1,LL i
1, R Mishra
1, K Ichinokawa
1,
Y Shoji
1, Y Matsumura
1, T Shichinohe
1, S Hirano
1, T Shinohara
2, T Itoh
3 and S Kondo
1
1Department of Surgical Oncology, Division of Cancer Medicine, Hokkaido University Graduate School of Medicine, N-15, W-7, Sapporo, Hokkaido 060-
8638, Japan;
2Department of pathology, Teine Keijinkai Hospital, Hokkaido 060-8638, Japan;
3Department of pathology, Hokkaido University Hospital,
Hokkaido 060-8648, Japan
CD4/8 status has been previously reported to be a critical factor in the prognosis of oesophageal squamous cell carcinoma (OSCC).
In the current study, we investigated the effect of regulatory T cells (Treg; Foxp3
þ lymphocytes) on the status of CD4
þ and CD8
þ
T cells in 122 patients with OSCC. Immunohistochemical analysis of Treg was performed using an antibody against Foxp3. The survival
rate for low Foxp3 patients was significantly lower than for high Foxp3 patients (P¼0.0028 by log-rank test), but Foxp3 status did not
significantly correlate with prognosis in CD4/8(þ/þ) patients or CD4/8(þ/ )o r(  /þ) patients (P¼0.5185 and 0.8479,
respectively, by log-rank test). We also found that Foxp3 status correlated with CD4/8 status (P¼0.0002 by w
2 test) and that the
variance of CD8/CD4 ratio in patients with low Foxp3 was larger than in patients with high Foxp3 (Po0.0001 by F-test). Thus, the
results do not support the idea that Treg suppress anti-tumour immunity in patients with OSCC. Rather, the CD8/CD4 ratio and
CD4/8 status appear to be critical factors in anti-tumour immunity. Furthermore, Treg numbers correlate with both the CD8/CD4
ratio and the CD4/8 status, suggesting that Treg number is not a factor to predict patient’s survival in OSCC.
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In previous studies, we found that cooperation between CD4
þ and
CD8
þ T cells appears to drastically improve the prognosis of
patients with oesophageal squamous cell carcinoma (OSCC) (Cho
et al, 2003). Thus, the host immune response against cancer cells
appears to play a critical role in the inhibition of recurrence and
determines the postsurgical prognosis in OSCC. Recent reports
suggested that thymic-derived CD4
þCD25
þ regulatory T cells
(Treg; Foxp3
þ lymphocytes) participate in the control of tumour
immunity, but whether Treg control tumour immunity in OSCC has
not been established.
Treg represent a minor fraction (5–10%) of the CD4
þ T cells,
and they maintain immune homoeostasis in immunotolerance and
control autoreactive T cells. In addition to their role in
autoimmunity, Treg participate in transplantation tolerance and
tumour immunity. Although the mechanisms of suppression by
Treg remain to be determined in vivo, many investigators have
reported that Treg can inhibit immune responses mediated by
CD4
þCD25
  T cells and CD8
þ T cells in vitro via cell–cell contact
(Sakaguchi et al, 1995; Sakaguchi, 2000; Shevach, 2002; Camara
et al, 2003; Anatomy et al, 2005). Treg express CD25 (interleukin-2
receptor a), glucocorticoid-induced tumour necrosis factor
receptor, and cytolytic T lymphocyte-associated antigen 4 on their
surface. The nuclei of these cells also contain Foxp3, which is a
member of the forkhead or winged helix family of transcription
factors. Foxp3 is reported to be a key regulatory gene for the
development and function of Treg and the most specific marker of
Treg (Chatila et al, 2000; Brunkow et al, 2001; Mchugh et al, 2002;
Fontenot et al, 2003; Hori et al, 2003; Khattri et al, 2003; Fontenot
and Rudensky, 2005).
Several studies in mice have shown that Treg inhibit the anti-
tumour immune response (Onizuka et al, 1999; Shimizu et al, 1999;
Nishikawa et al, 2005) and that depletion of Treg can enhance
effector T cell anti-tumour responses (Sutmuller et al,2 0 0 1 ;T a n a k a
et al, 2002). Additional studies have reported that the Treg
population increases in peripheral blood and tumour tissues from
patients with several types of human cancer (Woo et al, 2001;
Liyanage et al, 2002; Ichihara et al, 2003; Curiel et al, 2004; Kawaida
et al, 2005; Ormandy et al, 2005), but the relationship between the
Treg population and the prognosis has not been clarified in OSCC.
The purpose of this study, therefore, was to determine the effect of
Treg on CD4
þ and CD8
þ T cells in OSCC. The present study was
performed with same cohort as in Cho et al (2003).
MATERIALS AND METHODS
Patients and specimens
One hundred and twenty-two patients (105 male and 17 female;
mean age, 62.3 years) with primary OSCC underwent radical
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soesophagectomy between September 1989 and May 1999 at the
Department of Surgical Oncology, School of Medicine, Hokkaido
University or at an affiliated hospital (Department of Surgery,
Teine keijinkai Hospital and Department of Surgery, Hokkaido
Gastroenterology Hospital). Preoperative examination did not find
distant metastasis in any of the patients, and none of the patients
had received prior anticancer treatments. Cases of in-hospital
death were excluded from the current study. The clinical typing of
tumours was determined according to the tumour-node-metastasis
(TNM) classification system of the International Union Against
Cancer (Sobin and Wittekind, 2002). All tumour specimens were
fixed in 10% formalin and embedded in paraffin wax. One of the
deepest sections from each tumour was selected for evaluation, and
serial 4-mm thick sections were examined by immunohisto-
chemistry. All the informed consent process for immuno-
histochemical staining were conducted in accordance with the
guidelines of the Hokkaido University Institutional Review Board
Authorization for this study.
Immunohistochemistry
For immunohistochemical analysis, formalin-fixed and paraffin-
embedded specimens were deparaffinised in xylene and
dehydrated through a graded series from ethanol to water. For
antigen retrieval, sections were floated on 1mM EDTA buffer (pH
9.0) in a plastic container and then heated in a domestic pressure
cooker for 3min after it reached the maximum pressure. Once
cooled, the heat-treated sections were washed three times for 5min
each with PBS (pH 7.4). Before staining the sections, endogenous
peroxidase activity was eliminated by a 20-min incubation in 0.3%
hydrogen peroxide in methanol. After washing in PBS, specimens
were blocked with 10% normal goat serum (Nichirei Corporation,
Tokyo, Japan) for 30min and then incubated at room temperature
for 60min with 1:40 mouse anti-human Foxp3 antibody (clone
246A/E7; Abcam, Cambridge, UK) in antibody diluent (Dako-
Cytomation, Glostrup, Denmark). Normal adenoid tissue was used
as a positive control for Foxp3. After washing with PBS, the
sections were incubated for 60min at room temperature with a
biotinylated goat antibody to mouse immunoglobulin (Histofine
Simple Stain MAX PO [MALTI]; Nichirei Corporation, Tokyo,
Japan). After washing in PBS, immunohistochemical staining was
developed by incubating the sections in freshly prepared
3,30-diaminobenzidine tetrahydrochloride (Histofine Simple Stain
DAB Solution; Nichirei Corporation) for approximately 10min.
The sections were washed in distilled water, counterstained with
haematoxylin for 15s, and mounted in Permount (Micro Slides;
Muto-Glass, Tokyo, Japan). Mouse IgG1 (DakoCytomation,
Glostrup, Denmark) was used in place of the Foxp3 antibody for
negative controls.
Quantification of Treg
Immunohistochemically stained sections were evaluated under a
microscope (Olympus Optical Co. Ltd, Tokyo, Japan). The current
study was performed in a retrospective manner, but all specimens
were evaluated by two investigators blinded to the patients’ clinical
information. Treg were quantified by analyzing five different high
power fields ( 400). Between 0 and 848 Treg were detected in
the five fields, and the median (109) was used as a cutoff to define
the subgroups.
Statistical analysis
Statistical analysis was performed using the w
2 test. The Kaplan–
Meier method was used to estimate overall survival and survival
differences were analysed by the log-rank test based on the number
of immune cells. Univariate and multivariate analyses of immune
cells and clinicopathological features were performed using the
Cox proportional hazard regression model. The F-test was used to
analyse the variance in the CD8/CD4 ratio. The Mann–Whitney
U-test was used to analyse the number of Treg. In all cases, P-values
less than 0.05 were regarded as indicating statistical significance.
AB
CD
Figure 1 Immunohistochemical staining. (A) Positive control tonsil stained with anti-human Foxp3 antibody. (B) Negative control tonsil stained with
isotype-matched IgG. (C, D) OSCC stained with anti-human Foxp3 antibody at (C)  200 and (D)  400.
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(SAS Institute Inc., Cary, NC, USA).
RESULTS
Immunohistochemical staining of Treg
Figure 1 shows representative photomicrographs of immuno-
histochemical staining for Treg using an antibody to human Foxp3.
Treg were detected in cancer cell nests or in the stroma in contact
with cancer cells.
Correlation between Foxp3 status and clinicopathological
features
Correlations between Foxp3 status and various clinicopathological
features are summarised in Table 1. Foxp3 status was found to
correlate with CD4 status (P¼0.0186), CD8 status (P¼0.0021),
and CD4/8 status (P¼0.0002). No significant correlation was
found between Foxp3 status and age, gender, pathological data
according to TNM classification, or p-stage grouping.
Kaplan–Meier survival analysis of low Foxp3 and high
Foxp3 patients
Survival curves were constructed according to the Kaplan–Meier
method (Figure 2). In the 122 patients with OSCC (Figure 2A), the
survival rates for patients with low Foxp3 were significantly lower
than for patients with high Foxp3 (P¼0.0028 by log-rank test).
In CD4/8(þ/þ) patients (n¼44; Figure 2B) or CD4/8 (þ/ )o r
( /þ) patients (n¼34; Figure 2C), Foxp3 status was not
significantly related to the prognosis (P¼0.5185 and 0.8479,
respectively, by log-rank test). In CD4/8( / ) patients (n¼44;
Figure 2D), the survival rates for patients with low Foxp3 were
significantly lower than for patients with high Foxp3 (P¼0.0050
by log-rank test). Similar results were found in patients divided
into subgroups of p-stages I/II (P¼0.0018; Figure 2E) and III/IV
(P¼0.0352; Figure 2F).
Univariate and multivariate analyses
Univariate analysis for overall survival using a Cox regression
model identified T classification, N classification, M classification,
CD4 status, CD8 status, and Foxp3 status as significant predictors
of the prognosis. Multivariate analysis of the same set of patients
was performed for pathological predictors, CD4 status, CD8 status,
and Foxp3 status for survival time using the Cox regression model.
T classification, N classification, CD8 status, and Foxp3 status were
of independent prognostic value (Table 2). Although Foxp3 status
was not independent when multivariate analysis was performed
using CD4/8 status and Foxp3 as factors, Foxp3 status had
independent prognostic value in selected cases of CD4/8( / )
patients (Hazard ratio¼3.382; P¼0.0207; data not shown).
Correlation between CD4/8 status and the number of Treg
A significant correlation was found between CD4/8 status and the
number of Treg by the Mann–Whitney U-test (for CD4/8(þ/þ) vs
( /þ), P¼0.0021; for CD4/8 (þ/þ) vs CD4/8 ( / ), P¼0.0005;
Figure 3). The median value of the number of Treg in CD4/8
(þ/þ), CD4/8(þ/ ), CD4/8( /þ), and CD4/8( / ) patients
was 203, 93, 68 and 67 respectively.
Correlation between Foxp3 status and the variance on
CD8/CD4 ratio
In the 122 patients with OSCC (Figure 4A), the heterogeneity of the
variance in the CD8/CD4 ratio was significantly different between
high Foxp3 patients and low Foxp3 patients (Po0.0001 by F-test).
The variance on CD8/CD4 ratio of low Foxp3 patients (variance:
30.046) was larger than high Foxp3 patients (variance: 0.279) in the
122 patients with OSCC. In selected case of CD4/8( / ), similarly,
the variance on CD8/CD4 ratio was 58.073 in low Foxp3 patients
and 0.766 in high Foxp3 patients (Figure 4B).
Kaplan–Meier survival analysis according to the CD8/CD4
ratio
The patients were divided into four groups according to their CD8/
CD4 ratios (Figure 4C). The survival rates for patients with the
highest and lowest CD8/CD4 ratios were significantly lower than
for the other two groups (P¼0.0026 by log-rank test). In the CD4/
8( / ) patients (n¼44; Figure 4D), the CD8/CD4 ratio was not
significantly related to the prognosis (P¼0.3566 by log-rank test).
DISCUSSION
In recent years, factors that regulate immune responses to
malignant tumour cells have received a great deal of attention.
Several of these studies have shown that Treg are recruited to
Table 1 Correlation between clinicopathological features of the 122
patients with OSCC and the number of Foxp3 positive cells
Foxp3 positive cell
Low High
Variable No. of cases n¼61 n¼61 P-value
Age (Years)
o62 58 28 30 0.7169
X62 64 33 31
Gender
Male 105 53 52 0.7938
Female 17 8 9
pT classification
T1/T2 67 32 35 0.5852
T3/T4 55 29 26
pN classification
Negative 60 28 32 0.4688
Positive 62 33 29
pM classification
M0 101 50 51 0.8105
M1 21 11 10
P-Stage
I/II 76 38 38 40.9999
III/IVA 46 23 23
CD4 status
Abundant 61 24 37 0.0186
Scanty 61 37 24
CD8 status
Abundant 61 22 39 0.0021
Scanty 61 39 22
CD4/8 status
CD4/8(+/+) 44 12 32 0.0002
Others 78 49 29
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shuman carcinomas and they may influence the prognosis of cancer
patients (Woo et al, 2001; Liyanage et al, 2002; Ichihara et al, 2003;
Curiel et al, 2004; Kawaida et al, 2005; Ormandy et al, 2005). To
adequately evaluate antitumour immune function; however, multi-
ple factors should be evaluated simultaneously. Here, we found
that the CD8
þ T cell effect was significant only when CD4
þ T cells
were also present. This is the first report that has clarified the
correlation of Treg with CD4
þ and CD8
þ T cells in OSCC and
examined the effect of Treg on these T cells. In addition, we did not
find a correlation between Foxp3 status and TNM classification,
suggesting that Treg do not influence the progression of cancer.
Based on evidence from murine models, the prognosis of high
Foxp3 patients is expected to be poor (Onizuka et al, 1999; Shimizu
et al, 1999; Sutmuller et al, 2001; Tanaka et al, 2002; Nishikawa
et al, 2005); however the current results do not support this
hypothesis because the high Foxp3 patients had a dramatically
better prognosis than the low Foxp3 patients. Thus, the increase in
Treg seemed to be due to an increase in the total number of
S
u
r
v
i
v
a
l
 
r
a
t
e
 
(
%
)
Survival period (years) Survival period (years)
100
80
60
40
20
0
S
u
r
v
i
v
a
l
 
r
a
t
e
 
(
%
)
100
80
60
40
20
0
S
u
r
v
i
v
a
l
 
r
a
t
e
 
(
%
)
100
80
60
40
20
0
S
u
r
v
i
v
a
l
 
r
a
t
e
 
(
%
)
100
80
60
40
20
0
S
u
r
v
i
v
a
l
 
r
a
t
e
 
(
%
)
100
80
60
40
20
0
S
u
r
v
i
v
a
l
 
r
a
t
e
 
(
%
)
100
80
60
40
20
0
02468 0 2 4 6 8
02468
02468
02468
01234
P=0.5185 P=0.0028
P=0.8479 P=0.0050
High (n=61)
Low (n=61)
Low (n=12)
High (n=32)
High (n=12)
Low (n=22)
High (n=17)
Low (n=27)
P=0.0018 P=0.0352
High (n=37)
High (n=24)
Low (n=37)
Low (n=24)
AB
CD
EF
Figure 2 Kaplan–Meier analyses of overall survival according to the number of Tregs in (A) all patients (n¼122), (B) CD4/8(þ/þ) patients (n¼44),
(C) CD4/8(þ/ ) and ( /þ) patients (n¼34), (D) CD4/8 ( / ) patients (n¼44), (E) stage I and II patients (n¼74), and (F) stage III and IV patients
(n¼48).
Table 2 Univariate and multivariate analyses of immune cells and clinicopathological features using the Cox proportional hazard regression model
Univariate Multivariate
Variable Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value
Gender (male/female) 2.812 (0.872–9.070) 0.0835
Age (X62 vs o62) (years) 1.404 (0.783–2.519) 0.2543
pT classification (3/4 vs 1/2) 4.164 (2.238–7.747) o0.0001 2.564 (1.305–5.038) 0.0063
pN classification (1 vs 0) 5.880 (2.885–11.985) o0.0001 5.051 (2.273–11.236) o0.0001
pM classification (1 vs 0) 3.056 (1.615–5.780) 0.0006 1.067 (0.532–2.141) 0.8556
pStage (III/IV vs I/II) 7.828 (3.969–15.437) o0.0001
CD4 status (abundant vs scanty) 0.350 (0.184–0.664) 0.0013 0.778 (0.374–1.619) 0.5022
CD8 status (abundant vs scanty) 0.451 (0.248–0.819) 0.0089 0.502 (0.259–0.974) 0.0417
Foxp3 status (low vs high) 2.474 (1.338–4.577) 0.0039 2.239 (1.172–4.275) 0.0146
CD4/8 (CD4/8(+/+) vs others) 0.208 (0.088–0.492) 0.0003 0.250 (0.130–0.603) 0.0020
Foxp3 status (low vs high) 2.474 (1.338–4.577) 0.0039 1.784 (0.949–3.353) 0.0722
CI, confidence interval.
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sT lymphocytes, and Treg do not appear to suppress the anti-tumour
immune response. In fact, the number of Treg in CD4/8(þ/þ)
patients was significantly higher than in CD4/8( / ) patients and
CD4/8( /þ) patients, and survival curves divided on the basis of
Foxp3 status in CD4/8(þ/þ) patients were similar. Interestingly,
in CD4/8( / ) patients, the survival rates for low Foxp3 patients
were significantly lower than for high Foxp3 patients. Given these
results, it appears that the presence of Treg suggested a normal
antitumour immune response, and Treg do not appear to inhibit
the proliferation of tumour-specific T lymphocytes. Similar
results were shown in patients divided on the basis of p-stage.
Curiel et al (2004) reported that tumour cells produce the
chemokine CCL22, which mediates trafficking of Treg to the
tumour and that the percentage of Treg in CD4
þCD3
þ T cells is
higher in the later than the earlier stage of disease; however, we did
not find a correlation between p-stage and Foxp3 status, and high
Foxp3 patients had a better prognosis in both earlier stage and
advanced stage patients. Although the intratumor balance of Treg
and CD8
þ T cell has been shown to correlate with prognosis of
several cancer types such as ovarian cancer and hepatocellular
carcinoma (Sato et al 2005; Gao et al 2007), we did not find a
significant correlation between CD8
þ T cell/Treg ratio and
prognosis. These data also support the idea that Treg do not
suppress antitumour immunity in OSCC.
Various immunological factors must be considered to under-
stand the state of antitumour immunity. We previously reported
that the prognosis of the CD4/8(þ/þ) group is remarkably better
than that of the other groups (Cho et al, 2003). Around the same
time, Diederichsen Axel et al (2003) reported that a high CD8/CD4
ratio is associated with a better prognosis in colorectal cancer.
Furthermore, Piersma et al (2007)also reported that a higher CD8/
CD4 ratio is associated with the lack of tumour metastases in the
draining lymph nodes of cervical cancer patients. Therefore, it is
obvious that the balance of CD4
þ T cell and CD8
þ T cell is critical
for prognosis of patients with cancer. In the present study, the
favourable prognosis of high Foxp3 patients in the CD4/8( / )
group appears to be related to the CD8/CD4 ratio. When the
patients were divided into four groups on the basis of the CD8/CD4
ratio, the prognoses of the groups with the highest and lowest
ratios were poorer than those of the other two groups. In addition,
the CD8/CD4 ratio was disrupted in low Foxp3 patients with
poorer prognoses. Similar results were observed in the CD4/8
( / ) patients. These findings show that a suitable CD4/8 ratio
corresponds with a favourable prognosis and that it reflects the
immune response against OSCC.
In conclusion, the increase of infiltrating Treg in OSCC patients
is due to an increase in the total number of T lymphocytes, and the
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The median number of Tregs in CD4/8( / ), CD4/8( /þ), CD4/8
(þ/ ), and CD4/8(þ/þ) patients was 67, 68, 93 and 203, respectively.
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sresults did not support the idea that Treg suppress anti-tumour
immunity in patients with OSCC. Rather, the CD8/CD4 ratio and
CD4/8 status appear to be critical for anti-tumour immunity, and
infiltrating Treg correlates with both of these measures of anti-
tumour immune function in OSCC.
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